By: Marc Lobliner, IFBB Pro

Every once in a while, a study gets published that makes you step back and ask how it ever made it through peer review at all. The recent open label trial on Avela, which is a form of (R)-1,3-butanediol, is one of those studies. I have seen poorly designed research before, but this one stands out as one of the weakest and most misleading pieces of work in the ketone category.

For an ingredient that is trying to compete against real beta hydroxybutyrate, the research should be airtight. Instead, the flaws are so obvious that the conclusions cannot be taken seriously. Here is why this study is a complete mess and why brands should be very cautious about using it to make any claims.

No Control Group

The first and most damaging flaw is that the study has no control group. There is nothing to compare the treatment against. No placebo. No goBHB. No baseline testing under standardized conditions. Without a comparator, you cannot say the ingredient caused anything at all. This alone makes the data functionally useless.

Participants Were Employees of the Company Behind the Ingredient

Every participant was an employee of the company associated with the ingredient. Even if an outside coordinator collected the data, the conflict of interest is massive. Participants know what the company wants to see. That alone introduces bias into every measurement and every subjective report.

Self Testing at Home With No Oversight

All testing was done by the subjects in their own homes. They performed their own finger stick tests, reported their own symptoms, and entered their own data. There was no clinical supervision. Not surprisingly, the data has multiple errors, including at least one entry that had to be corrected because the level was impossible for a living human. A study is only as strong as the quality of its measurements. These measurements are not trustworthy.

A Dosing Protocol Designed to Inflate Results

The study used a massive 34.5 gram dose of 1,3-butanediol on an empty stomach. No one in the real world uses the ingredient in this way. This kind of dosing is designed to push ketone readings as high as possible. It is not representative of actual consumer use and creates misleading expectations about what the ingredient can realistically deliver.

Invalid Ketone Measurements

The study used a home ketone meter that cannot accurately read levels above a certain threshold. Several readings in the study exceeded that limit. That means the number reported cannot be validated. When your own measuring tool cannot confirm the data you are using to make claims, the data should be thrown out.

Side Effects Were Ignored in the Conclusion

Subjects reported nausea, headaches, dizziness, and gastrointestinal distress. Despite this, the authors described the treatment as well tolerated. When you see a study ignoring its own side effect data, you know something is wrong.

Poor Ketone Conversion Compared to goBHB

The ingredient being studied, (R)-1,3-butanediol, is far less efficient at producing beta hydroxybutyrate than goBHB. The body must convert it, and that conversion is slow and inconsistent. The study avoided comparing it to actual BHB salts, and that omission speaks volumes. If there was confidence in performance, a goBHB comparison would be the first thing included.

Why This Matters

Brands rely on clean, strong data to make decisions. Consumers rely on brands to use ingredients that actually deliver benefits. When studies like this get published, they create confusion and misrepresent an ingredient’s true value. Avela simply cannot compete with goBHB when it comes to efficiency, consistency, purity, or performance.

goBHB is the most clinically supported exogenous ketone in the world because it delivers real beta hydroxybutyrate directly, cleanly, and predictably. This study tries to position an inferior pathway as something groundbreaking when the data does not support it in any serious way.

The Bottom Line

This study is one of the weakest I have ever reviewed. Poor design, biased participants, inaccurate measurements, unrealistic dosing, ignored side effects, and a complete lack of meaningful comparison make it impossible to use for any legitimate claims. Brands deserve better research than this. Consumers deserve ingredients backed by real science.

If you want results you can trust, stick with goBHB. It remains the standard for exogenous ketones, and no amount of weak research will change that.